$1.90
$0.05 (+2.70%)
$1.81Day Range$1.90
Key Statistics
Market Cap
$216.12M
Shares Outstanding
116.8M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jan 15, 2019
Round Lot
100
Locale
US
Trading Data
Day Open
$1.85
Day High
$1.90
Day Low
$1.81
Volume
1.58M
VWAP
$1.85
Prev Close
$1.85
Transactions
--
Acc. Volume
--
About Cardiol Therapeutics Inc. Class A Common Shares
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.
Identifiers
- CIK
- 0001702123
- Composite FIGI
- BBG00N2N8310
- Share Class FIGI
- BBG00M0GNQ75
- Ticker Root
- CRDL
About Cardiol Therapeutics Inc. Class A Common Shares (CRDL) Stock
Cardiol Therapeutics Inc. Class A Common Shares (CRDL) closed the 2026-09-16 session at $1.90, up 2.70% versus the previous close (+0.05). The stock opened at $1.85 and traded between $1.81 and $1.90 during that session. Session trading volume was 1.6M shares. The volume-weighted average price (VWAP) is $1.85.
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.
Cardiol Therapeutics Inc. Class A Common Shares has a market capitalization of $216.1 million. CRDL is listed on the XNAS exchange. The company employs approximately 18 people. The recorded listing date is 2019-01-15.
On this page you can find market CRDL stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors.